What type of study is this?

This is a Experimental Study study.

September 19, 2025Open Access

Construction of Probiotic Escherichia coli Nissle 1917 as a Next- Generation Expression Platform and Its Application in Therapeutic Protein Production

View Full Paper

Ask AI

Bookmark

Authors

This research utilizes escherichia coli nissle 1917 to produce therapeutic proteins, suggesting a novel low-LPS platform.

The engineered strain ecN::T7ΔompTΔiclRΔarcA produced 3.2-fold more protein than its parental strain, indicating enhanced yield.
Mutant ecN::T7ΔompTΔiclRΔarcA achieved 89.3% of BL21(DE3)’s interferon α-2b titer and maintained full biological activity.
Using crispr/cas9 technology, critical genes were edited to improve protein synthesis in ecN, demonstrating a novel approach.
This platform reduces the need for extensive lipopolysaccharide removal, implying cost-effective and compliant biomanufacturing solutions.

Wang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 19, 2025Open Access

View Full Paper

Ask AI

Bookmark

Authors

This research utilizes escherichia coli nissle 1917 to produce therapeutic proteins, suggesting a novel low-LPS platform.

The engineered strain ecN::T7ΔompTΔiclRΔarcA produced 3.2-fold more protein than its parental strain, indicating enhanced yield.
Mutant ecN::T7ΔompTΔiclRΔarcA achieved 89.3% of BL21(DE3)’s interferon α-2b titer and maintained full biological activity.
Using crispr/cas9 technology, critical genes were edited to improve protein synthesis in ecN, demonstrating a novel approach.
This platform reduces the need for extensive lipopolysaccharide removal, implying cost-effective and compliant biomanufacturing solutions.

Wang et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark